2026 Q2 - tulosraportti
85 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
4,49%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 500 | ||
| 2 570 | ||
| 1 465 | ||
| 965 | ||
| 500 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 4.11. | 6 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. | ||
2025 Q3 - tulosraportti 5.11.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·24 min sittenLundbeck is up 15% since Lars Fruergaard was mentioned as future chairman of the board - Novo is down ÷40 since he stepped down. It looks like a pattern.Most people would have been more confident with a share price above 400 than 260. Lars Fruergaard left Novo in a better place than when he took over the management - How do you think it has gone since?
·27 min sittenNot a buy recommendation. But the story of Genmab is probably proof that even though things look bleak, it turns around again for most well-managed companies. From around price 1200 to price barely 4000. Novo Nordisk has after all said for a long time that it will take until 2027/2028 before that turnaround with savings etc. has materialized. So actually one should just buy some NN and log out of one's account for a couple of years, and let time work for oneself. I myself have 129 shares at close to break-even. I am keeping them and accumulating myself continuously as long as it is at the current price +- .The history of ØK shows just how wrong it can go if a company loses the competition.
·32 min sitten🚀🚀 NOVO NORDISK - COULD THIS BE THE COMEBACK OF THE YEAR? 🔥 The market may have underestimated Novo Nordisk. While everyone is staring at Eli Lilly, Novo could be the one to surprise when the numbers are released. 💥 💉 Strong results. 📈 Better outlook than expected. 🔥 A comeback the market hasn't priced in. If Novo delivers better than feared - and shows that its competitiveness remains intact - the stock could see a strong rebound. 10% up? 🚀 That is a possible scenario if the results and guidance surprise positively. But nothing is guaranteed, and disappointments can swing the other way. The market often looks backward. The biggest movements come when the future turns out better than expectations. 🎯 The question is not just what Novo delivers - but what the market expects them to deliver. NOVO NORDISK: Is this when pessimism has gone too far? 🇩🇰🚀 #NovoNordisk #NOVO #Investering #Aksjer #Comeback
With the growth LLY has shown yet again... Again, we just have to be happy if Novo hasn't lost corresponding percentages in market share. In Q2 LLY also had massive growth, but Novo stood still. If Novo hasn't found a way to make people choose their products, we'll see the same thing again. The market is booming, but Novo is not.
·45 min sittenYou just have to say that Lilly is doing well! They are bold as brass and skilled at conquering the American market. One can hope that Novo can get just a bit of Lilly's momentum, a slightly faster rollout of the pill and that the share price will then get a bump upwards. The market is huge and there should be room for multiple players to cover different needs! I am all in on Novo leading up to the financial report.- ·51 min sittenIf the financial report disappoints, will it test 231 again? Considering buying more.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 99 600 | 99 600 | 0 | 99 600 |
| Anonyymi | 6 207 772 | 6 207 772 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 99 600 | 99 600 | 0 | 99 600 |
| Anonyymi | 6 207 772 | 6 207 772 | 0 | 0 |
2026 Q2 - tulosraportti
85 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
4,49%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·24 min sittenLundbeck is up 15% since Lars Fruergaard was mentioned as future chairman of the board - Novo is down ÷40 since he stepped down. It looks like a pattern.Most people would have been more confident with a share price above 400 than 260. Lars Fruergaard left Novo in a better place than when he took over the management - How do you think it has gone since?
- ·27 min sittenNot a buy recommendation. But the story of Genmab is probably proof that even though things look bleak, it turns around again for most well-managed companies. From around price 1200 to price barely 4000. Novo Nordisk has after all said for a long time that it will take until 2027/2028 before that turnaround with savings etc. has materialized. So actually one should just buy some NN and log out of one's account for a couple of years, and let time work for oneself. I myself have 129 shares at close to break-even. I am keeping them and accumulating myself continuously as long as it is at the current price +- .The history of ØK shows just how wrong it can go if a company loses the competition.
- ·32 min sitten🚀🚀 NOVO NORDISK - COULD THIS BE THE COMEBACK OF THE YEAR? 🔥 The market may have underestimated Novo Nordisk. While everyone is staring at Eli Lilly, Novo could be the one to surprise when the numbers are released. 💥 💉 Strong results. 📈 Better outlook than expected. 🔥 A comeback the market hasn't priced in. If Novo delivers better than feared - and shows that its competitiveness remains intact - the stock could see a strong rebound. 10% up? 🚀 That is a possible scenario if the results and guidance surprise positively. But nothing is guaranteed, and disappointments can swing the other way. The market often looks backward. The biggest movements come when the future turns out better than expectations. 🎯 The question is not just what Novo delivers - but what the market expects them to deliver. NOVO NORDISK: Is this when pessimism has gone too far? 🇩🇰🚀 #NovoNordisk #NOVO #Investering #Aksjer #ComebackWith the growth LLY has shown yet again... Again, we just have to be happy if Novo hasn't lost corresponding percentages in market share. In Q2 LLY also had massive growth, but Novo stood still. If Novo hasn't found a way to make people choose their products, we'll see the same thing again. The market is booming, but Novo is not.
- ·45 min sittenYou just have to say that Lilly is doing well! They are bold as brass and skilled at conquering the American market. One can hope that Novo can get just a bit of Lilly's momentum, a slightly faster rollout of the pill and that the share price will then get a bump upwards. The market is huge and there should be room for multiple players to cover different needs! I am all in on Novo leading up to the financial report.
- ·51 min sittenIf the financial report disappoints, will it test 231 again? Considering buying more.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 500 | ||
| 2 570 | ||
| 1 465 | ||
| 965 | ||
| 500 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 4.11. | 6 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. | ||
2025 Q3 - tulosraportti 5.11.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 99 600 | 99 600 | 0 | 99 600 |
| Anonyymi | 6 207 772 | 6 207 772 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 99 600 | 99 600 | 0 | 99 600 |
| Anonyymi | 6 207 772 | 6 207 772 | 0 | 0 |
2026 Q2 - tulosraportti
85 päivää sitten
‧1 t 2 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 4.11. | 6 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. | ||
2025 Q3 - tulosraportti 5.11.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
3,75 DKK/osake
Viimeisin osinko
4,49%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·24 min sittenLundbeck is up 15% since Lars Fruergaard was mentioned as future chairman of the board - Novo is down ÷40 since he stepped down. It looks like a pattern.Most people would have been more confident with a share price above 400 than 260. Lars Fruergaard left Novo in a better place than when he took over the management - How do you think it has gone since?
- ·27 min sittenNot a buy recommendation. But the story of Genmab is probably proof that even though things look bleak, it turns around again for most well-managed companies. From around price 1200 to price barely 4000. Novo Nordisk has after all said for a long time that it will take until 2027/2028 before that turnaround with savings etc. has materialized. So actually one should just buy some NN and log out of one's account for a couple of years, and let time work for oneself. I myself have 129 shares at close to break-even. I am keeping them and accumulating myself continuously as long as it is at the current price +- .The history of ØK shows just how wrong it can go if a company loses the competition.
- ·32 min sitten🚀🚀 NOVO NORDISK - COULD THIS BE THE COMEBACK OF THE YEAR? 🔥 The market may have underestimated Novo Nordisk. While everyone is staring at Eli Lilly, Novo could be the one to surprise when the numbers are released. 💥 💉 Strong results. 📈 Better outlook than expected. 🔥 A comeback the market hasn't priced in. If Novo delivers better than feared - and shows that its competitiveness remains intact - the stock could see a strong rebound. 10% up? 🚀 That is a possible scenario if the results and guidance surprise positively. But nothing is guaranteed, and disappointments can swing the other way. The market often looks backward. The biggest movements come when the future turns out better than expectations. 🎯 The question is not just what Novo delivers - but what the market expects them to deliver. NOVO NORDISK: Is this when pessimism has gone too far? 🇩🇰🚀 #NovoNordisk #NOVO #Investering #Aksjer #ComebackWith the growth LLY has shown yet again... Again, we just have to be happy if Novo hasn't lost corresponding percentages in market share. In Q2 LLY also had massive growth, but Novo stood still. If Novo hasn't found a way to make people choose their products, we'll see the same thing again. The market is booming, but Novo is not.
- ·45 min sittenYou just have to say that Lilly is doing well! They are bold as brass and skilled at conquering the American market. One can hope that Novo can get just a bit of Lilly's momentum, a slightly faster rollout of the pill and that the share price will then get a bump upwards. The market is huge and there should be room for multiple players to cover different needs! I am all in on Novo leading up to the financial report.
- ·51 min sittenIf the financial report disappoints, will it test 231 again? Considering buying more.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 500 | ||
| 2 570 | ||
| 1 465 | ||
| 965 | ||
| 500 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 99 600 | 99 600 | 0 | 99 600 |
| Anonyymi | 6 207 772 | 6 207 772 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 99 600 | 99 600 | 0 | 99 600 |
| Anonyymi | 6 207 772 | 6 207 772 | 0 | 0 |